John M. Kirkwood

91.4k total citations · 16 hit papers
687 papers, 46.4k citations indexed

About

John M. Kirkwood is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, John M. Kirkwood has authored 687 papers receiving a total of 46.4k indexed citations (citations by other indexed papers that have themselves been cited), including 488 papers in Oncology, 306 papers in Immunology and 284 papers in Molecular Biology. Recurrent topics in John M. Kirkwood's work include Immunotherapy and Immune Responses (261 papers), Cancer Immunotherapy and Biomarkers (213 papers) and CAR-T cell therapy research (203 papers). John M. Kirkwood is often cited by papers focused on Immunotherapy and Immune Responses (261 papers), Cancer Immunotherapy and Biomarkers (213 papers) and CAR-T cell therapy research (203 papers). John M. Kirkwood collaborates with scholars based in United States, Australia and Germany. John M. Kirkwood's co-authors include Michael B. Atkins, Vernon K. Sondak, Sanjiv S. Agarwala, Marc S. Ernstoff, Ahmad A. Tarhini, Charles M. Balch, John F. Thompson, Merrick I. Ross, Jeffrey E. Gershenwald and Cindy Sander and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

John M. Kirkwood

672 papers receiving 45.4k citations

Hit Papers

Final Version of 2009 AJCC Melanoma Staging and Classi... 1999 2026 2008 2017 2009 2001 2001 2017 2017 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Final Version of 2009 AJCC Melanoma Staging and Classification
    2009 3.3k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
  2. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
    2001 2.0k citations Charles M. Balch, Antônio C. Buzaid et al. Journal of Clinical Oncology profile →
  3. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
    2001 1.8k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
  4. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
    2017 1.4k citations Jeffrey E. Gershenwald, Richard A. Scolyer et al. CA A Cancer Journal for Clinicians profile →
  5. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
    2017 1.1k citations Antoni Ribas, Reinhard Dummer et al. profile →
  6. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
    2010 1.0k citations Julien Fourcade, Zhaojun Sun et al. The Journal of Experimental Medicine profile →
  7. High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
    2000 658 citations John M. Kirkwood, Vernon K. Sondak et al. Journal of Clinical Oncology profile →
  8. High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801
    2001 653 citations John M. Kirkwood, Vernon K. Sondak et al. Journal of Clinical Oncology profile →
  9. TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
    2015 608 citations Joë-Marc Chauvin, Ornella Pagliano et al. profile →
  10. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
    2004 598 citations Lawrence E. Flaherty, John M. Kirkwood et al. Journal of Clinical Oncology profile →
  11. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
    1999 542 citations Lynn M. Schuchter, John M. Kirkwood et al. Journal of Clinical Oncology profile →
  12. Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
    2008 534 citations Sandra J. Lee, James Moon et al. Journal of Clinical Oncology profile →
  13. Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
    2017 432 citations Cindy Sander, John M. Kirkwood et al. profile →
  14. Immunotherapy in Melanoma: Recent Advances and Future Directions
    2023 125 citations John M. Kirkwood et al. profile →
  15. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity
    2024 110 citations John M. Kirkwood et al. profile →
  16. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
    2024 75 citations Cindy Sander, Arivarasan Karunamurthy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John M. Kirkwood United States 104 31.3k 18.8k 17.9k 4.8k 4.4k 687 46.4k
Dirk Schadendorf Germany 101 27.6k 0.9× 15.5k 0.8× 21.3k 1.2× 3.5k 0.7× 4.5k 1.0× 982 46.5k
Michael B. Atkins United States 91 25.3k 0.8× 12.0k 0.6× 16.0k 0.9× 3.5k 0.7× 12.6k 2.8× 577 40.7k
Reinhard Dummer Switzerland 100 22.4k 0.7× 14.7k 0.8× 19.1k 1.1× 6.5k 1.4× 3.4k 0.8× 951 44.0k
Seth M. Steinberg United States 124 29.1k 0.9× 12.8k 0.7× 15.6k 0.9× 4.1k 0.9× 13.6k 3.1× 864 58.9k
Donald L. Morton United States 86 22.7k 0.7× 8.8k 0.5× 10.4k 0.6× 6.8k 1.4× 3.7k 0.8× 448 33.4k
Arlene H. Sharpe United States 130 28.8k 0.9× 47.7k 2.5× 16.3k 0.9× 5.9k 1.2× 4.6k 1.0× 408 75.8k
Richard A. Scolyer Australia 84 21.3k 0.7× 6.6k 0.4× 13.3k 0.7× 4.1k 0.8× 3.8k 0.9× 707 30.6k
Claus Garbe Germany 93 21.3k 0.7× 7.0k 0.4× 15.0k 0.8× 6.3k 1.3× 2.6k 0.6× 750 34.4k
Alexander M.M. Eggermont Netherlands 72 18.5k 0.6× 6.7k 0.4× 9.4k 0.5× 3.5k 0.7× 3.1k 0.7× 389 25.8k
Keith T. Flaherty United States 92 24.8k 0.8× 7.1k 0.4× 23.3k 1.3× 2.5k 0.5× 6.3k 1.4× 518 39.7k

Countries citing papers authored by John M. Kirkwood

Since Specialization
Citations

This map shows the geographic impact of John M. Kirkwood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Kirkwood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Kirkwood more than expected).

Fields of papers citing papers by John M. Kirkwood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Kirkwood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Kirkwood. The network helps show where John M. Kirkwood may publish in the future.

Co-authorship network of co-authors of John M. Kirkwood

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Kirkwood. A scholar is included among the top collaborators of John M. Kirkwood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Kirkwood. John M. Kirkwood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kashani–Sabet, Mohammed, et al.. (2025). Cutaneous Melanoma. JAMA. 334(23). 2113–2113. 1 indexed citations
2.
Schadendorf, Dirk, Jason J. Luke, Paolo A. Ascierto, et al.. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for ImmunoTherapy of Cancer. 12(3). e007501–e007501. 5 indexed citations
3.
Karunamurthy, Arivarasan, Douglas J. Hartman, Hong Wang, et al.. (2024). Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy. The Oncologist. 29(7). 619–628. 4 indexed citations
4.
Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Immuno-Oncology Technology. 20. 100591–100591. 7 indexed citations
5.
Maji, Santanu, Amit Kumar, Praveen Bhoopathi, et al.. (2023). Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis. Molecular Cancer Therapeutics. 22(10). 1115–1127. 4 indexed citations
6.
Bartlett, Edmund K., Douglas Grossman, Susan M. Swetter, et al.. (2022). Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. Annals of Surgical Oncology. 29(9). 5948–5956. 2 indexed citations
7.
Chauvin, Joë-Marc, Mignane Ka, Ornella Pagliano, et al.. (2020). IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clinical Cancer Research. 26(20). 5520–5533. 114 indexed citations
8.
Samlowski, Wolfram E., James Moon, Michael B. Atkins, et al.. (2017). High frequency of brain metastases after adjuvant therapy for high‐risk melanoma. Cancer Medicine. 6(11). 2576–2585. 24 indexed citations
9.
Kashani–Sabet, Mohammed, Mehdi Nosrati, James R. Miller, et al.. (2017). Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clinical Cancer Research. 23(22). 6888–6892. 22 indexed citations
10.
Averbook, Bruce J., Sandra J. Lee, Keith A. Delman, et al.. (2013). Pediatric melanoma: Analysis of an international registry. Cancer. 119(22). 4012–4019. 53 indexed citations
11.
Slingluff, Craig L., Charles Lee, Fengmin Zhao, et al.. (2013). A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602). Clinical Cancer Research. 19(15). 4228–4238. 90 indexed citations
12.
Kirkwood, John M., Lisa H. Butterfield, Ahmad A. Tarhini, et al.. (2012). Immunotherapy of cancer in 2012. CA A Cancer Journal for Clinicians. 62(5). 309–335. 345 indexed citations
13.
Flaherty, Keith T., Sandra J. Lee, Fengmin Zhao, et al.. (2012). Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. Journal of Clinical Oncology. 31(3). 373–379. 160 indexed citations
14.
Kirkwood, John M., Lars Bastholt, Caroline Robert, et al.. (2011). Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. Clinical Cancer Research. 18(2). 555–567. 218 indexed citations
15.
Fourcade, Julien, Zhaojun Sun, Mourad Benallaoua, et al.. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients. The Journal of Experimental Medicine. 207(10). 2175–2186. 1032 indexed citations breakdown →
16.
Balch, Charles M., Jeffrey E. Gershenwald, Seng-Jaw Soong, et al.. (2009). Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology. 27(36). 6199–6206. 3342 indexed citations breakdown →
17.
Slingluff, Craig L., Gina R. Petroni, Walter C. Olson, et al.. (2009). Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial. Clinical Cancer Research. 15(22). 7036–7044. 129 indexed citations
18.
Sætrom, Pål, Jacob Biesinger, David Smith, et al.. (2009). A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis. Cancer Research. 69(18). 7459–7465. 118 indexed citations
19.
Alexandrescu, Doru T, Karl D. Lewis, Wolfram E. Samlowski, et al.. (2007). A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.. Molecular Cancer Therapeutics. 6. 4 indexed citations
20.
Kokkinakis, Demetrius M., Anthony G. Brickner, John M. Kirkwood, et al.. (2006). Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress. Molecular Cancer Research. 4(8). 575–589. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dirk Schadendorf Breakdown of academic impact, for papers by Michael B. Atkins Breakdown of academic impact, for papers by Reinhard Dummer Breakdown of academic impact, for papers by Seth M. Steinberg Breakdown of academic impact, for papers by Donald L. Morton Breakdown of academic impact, for papers by Arlene H. Sharpe Breakdown of academic impact, for papers by Richard A. Scolyer Breakdown of academic impact, for papers by Claus Garbe Breakdown of academic impact, for papers by Alexander M.M. Eggermont Breakdown of academic impact, for papers by Keith T. Flaherty
Rankless by CCL
2026